Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy.
We report on the case of a patient with a diagnosis of an uncommon breast tumour, namely a radiation-induced angiosarcoma, which was primarily refractory to anthracycline-based chemotherapy, but highly sensitive to docetaxel. Although the sarcomas in general tend to be relatively refractory to taxanes, there is some evidence that the angiosarcomas may be sensitive to these agents. This is particularly well documented with paclitaxel, but may also be the case with docetaxel.
Mano
Max S
MS
Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, UK. max.mano@northglasgow.scot.nhs.uk
Fraser
Ghislaine
G
Kerr
Janet
J
Gray
Maureen
M
Evans
Vicky
V
Kazmi
Ather
A
Canney
Peter
P
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil